Uterine Fibroids
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The progesterone receptor gene polymorphism, PROGINS, may be a factor related to the development of uterine fibroids.
|
17224149 |
2007 |
Uterine Fibroids
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Analysis of estrogen receptor (ERalpha and ERbeta) and progesterone receptor (PR) polymorphisms in uterine leiomyomas.
|
12552233 |
2003 |
Uterine Fibroids
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Peripheral blood DNA was analyzed for the frequency of both progesterone receptor single nucleotide polymorphisms in 270 women with uterine leiomyomas compared with 163 control women without uterine leiomyomas.
|
18691687 |
2008 |
Uterine Fibroids
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The history and use of the progesterone receptor modulator ulipristal acetate for heavy menstrual bleeding with uterine fibroids.
|
28169130 |
2017 |
Uterine Fibroids
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The purpose of this study was to analyze the effect of ERα-351 XbaI A/G, ERα-397 PvuII T/C, and progesterone receptor (PGR) PROGINS polymorphisms on the development of leiomyomas.
|
30390345 |
2019 |
Uterine Fibroids
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Uterine fibroids (UFs) may be treated with progesterone receptor modulators (PRMs), which have been shown to reduce heavy menstrual bleeding and the size of UFs.
|
28185997 |
2017 |
Uterine Fibroids
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The TC genotype of the ERβ receptor polymorphism and the GA and AA genotypes of the PGR receptor polymorphism and their respective hormonal levels can be developed as markers in the prediction of uterine fibroids.
|
26715264 |
2016 |
Uterine Fibroids
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Conversely, the highest RANKL levels were found in the PR-rich leiomyoma intermediate cell (LIC) population.
|
29741640 |
2018 |
Uterine Fibroids
|
0.100 |
GeneticVariation
|
group |
BEFREE |
MEDLINE using PubMed, Science Direct, and Google Scholar databases was searched using the terms "PROGINS," "progesterone receptor," "polymorphism," and "leiomyoma."
|
29630404 |
2018 |
Uterine Fibroids
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We observed no significant difference of the PGR*T1/T2 genotypes and allele frequencies between leiomyoma and other two groups.
|
15807882 |
2005 |
Uterine Fibroids
|
0.100 |
Biomarker
|
group |
BEFREE |
The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids.
|
29274830 |
2018 |
Uterine Fibroids
|
0.100 |
Biomarker
|
group |
BEFREE |
The selective progesterone receptor modulator, ulipristal acetate, has been reported to decrease the size of leiomyomas in clinical trials.
|
30567472 |
2019 |
Uterine Fibroids
|
0.100 |
Biomarker
|
group |
BEFREE |
We demonstrated previously that LAT2 is a progesterone receptor target gene involved in leiomyoma growth.
|
20601542 |
2010 |
Uterine Fibroids
|
0.100 |
Biomarker
|
group |
BEFREE |
In all cases, pulmonary tumors had benign histology and immunohistochemical profiles (estrogen receptor positive, progesterone receptor positive, and very low proliferative index) identical to uterine leiomyoma.
|
16357844 |
2006 |
Uterine Fibroids
|
0.100 |
Biomarker
|
group |
BEFREE |
Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate.
|
30539001 |
2018 |
Uterine Fibroids
|
0.100 |
Biomarker
|
group |
BEFREE |
Progesterone receptor modulators, such as mifepristone are useful and well tolerated in reducing leiomyoma volume although with large individual variation.
|
24324590 |
2013 |
Uterine Fibroids
|
0.100 |
Biomarker
|
group |
BEFREE |
Studies testing various selective progesterone receptor modulators for the treatment of leiomyomas are also highlighted.
|
21672608 |
2012 |
Uterine Fibroids
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, perilipin-2 (PLIN2) was identified as a critical target gene of the progesterone receptor; however, its function in the pathogenesis of fibroids is unknown.
|
31504629 |
2019 |
Uterine Fibroids
|
0.100 |
Biomarker
|
group |
BEFREE |
Transthoracic needle biopsy was performed and the resected lesion consisted of benign spindle cells was positive for estrogen receptor (ER) and progesterone receptor (PR) and was diffuse positive for actin and desmin by immunohistochemical (IHC) staining, suggesting leiomyoma.
|
28203428 |
2017 |
Uterine Fibroids
|
0.100 |
Biomarker
|
group |
BEFREE |
This indicates that PROGINS can be considered as a predisposing risk marker for breast cancer but not for endometriosis and uterine fibroids.
|
17522428 |
2007 |
Uterine Fibroids
|
0.100 |
Biomarker
|
group |
BEFREE |
The amount of cells positively stained for PR-AB and PR-B in fibroids and myometrium decreased after GnRH-a treatment compared with in the proliferative phase.
|
12413982 |
2002 |
Uterine Fibroids
|
0.100 |
Biomarker
|
group |
BEFREE |
Distribution of the A and B forms of the progesterone receptor messenger ribonucleic acid and protein in uterine leiomyomata and adjacent myometrium.
|
9159448 |
1997 |
Uterine Fibroids
|
0.100 |
Biomarker
|
group |
BEFREE |
The selective progesterone receptor modulator asoprisnil suppresses uterine bleeding and decreases leiomyoma volume while maintaining follicular phase estrogen concentrations.
|
19176543 |
2009 |
Uterine Fibroids
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, treatment with selective progesterone receptor modulators has shown promising results with shrinkage of uterine leiomyomas and a prolonged clinical effect.
|
28697115 |
2017 |
Uterine Fibroids
|
0.100 |
Biomarker
|
group |
BEFREE |
Ulipristal acetate (UPA) a selective progesterone receptor (PR) modulator (SPRM) reduce the size of UFs, inhibit ovulation and lead to amenorrhea.
|
31754172 |
2019 |